IVT PCV-25 / Inventprise - LARVOL DELTA

Safety and immunogenicity of a 25-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naive healthy adults: Results from 2 randomised, controlled clinical trials. (PubMed, Vaccine) - P2 | "Multiple formulations of IVT PCV-25, a vaccine designed to cover pneumococcal serotypes prevalent in LMICs, were well tolerated and immunogenic in healthy adults. As adult immunogenicity is not fully predictive for infants, further development will evaluate safety and immunogenicity in the target infant population."

Clinical • Journal • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Not yet recruiting | Sponsor: Inventprise Inc.

New P2 trial • Infectious Disease • Pneumococcal Infections

PUTATIVE NOVEL SEROTYPES IN SEROGROUP 33 (ISPPD 2024) - "Background: Serotype 33F, a well-recognized invasive pneumococcal serotype is included in the higher valent pneumococcal conjugate vaccines (PCV) like PCV15, PCV20, PCV24, and IVT-25... While the prevalence of newly described serotype 33E is low within the GPS database, we identified four putative novel serotypes in serogroup 33 that warrant further characterization."

Infectious Disease • Pneumococcal Infections

GENOMIC CHARACTERISATION OF INVASIVE STREPTOCOCCUS PNEUMONIAE IN CHILDREN IN SLOVENIA (ISPPD 2024) - "In the post-PCV13 population, higher-valent PCV15, PCV20, PCV24 and IVT-25 will increase serotype coverage to 47.3% (44/93), 59.1% (55/93), 60.2% (56/93), 74.2% (69/93), respectively. In Slovenia, proportional decreases in vaccine serotypes among IPD cases in children after the introduction of PCV10/PCV13 was observed. Further surveillance is needed to confirm the emerging serotypes."

Clinical • Infectious Disease • Pneumococcal Infections • Pneumonia

GENOMIC CHARACTERISATION OF STREPTOCOCCUS PNEUMONIAE POPULATION CAUSING INVASIVE DISEASE IN LEBANON (ISPPD 2024) - "Higher valency vaccines such as PCV24 (68%; 56/82) and IVT25 would offer the highest serotype coverage in the PCV13 period. Vaccine effectiveness was demonstrated by the change in pneumococcal serotypes post-PCV13 introduction."

Clinical • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Septic Shock

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P2 | N=220 | Not yet recruiting | Sponsor: Inventprise Inc.

New P2 trial • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1 | N=65 | Completed | Sponsor: Inventprise Inc. | Recruiting ➔ Completed | Phase classification: P1/2 ➔ P1 | N=520 ➔ 65 | Trial completion date: Feb 2025 ➔ Jul 2023 | Trial primary completion date: Sep 2024 ➔ Jul 2023

Enrollment change • Phase classification • Trial completion • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1/2 | N=520 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

IVT PCV-25: Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine (clinicaltrials.gov) - P1/2 | N=520 | Not yet recruiting | Sponsor: Inventprise Inc.

New P1/2 trial • Infectious Disease • Pneumococcal Infections